rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2003-10-7
|
pubmed:abstractText |
Despite the use of modern immunosuppressive drugs, acute liver rejection (AR) continues to affect up to 70% of transplant recipients. The aim of this retrospective study was to assess the incidence of acute rejection episodes in patients treated with different immunosuppressive protocols. In our series, 37.3% of patients developed a clinical episode of AR. Analysis of immunosuppression has shown that the most effective immunosuppressive protocols, with regard to prevention of AR, include: antibody anti-IL-2R (anti-IL-2R) + tacrolimus (Tac) + mycophenolate mofetil (MMF) + prednisolone (Pred); anti-IL-2R + tacrolimus (Tac) + Pred; or Tac + Pred (25% vs 28.6% vs 30.4%, respectively). The highest rate of AR (66.6%) was observed among patients with anti-IL-2R and Tac but no steroid treatment, mostly (77.7%) in the initial period after liver transplantation. There were no statistical differences in liver function tests between the group treated with a CsA-based versus a Tac-based therapy. Strong immunosuppression contributed to a relatively low incidence of clinical AR in our series. The lowest rate of AR was observed among patients treated with anti-IL-2R antibody. Tac, and Pred. Deprivation of steroids in the early phase after liver transplantation substantially increased the risk of acute rejection episodes despite the use of anti-CD25. There were no statistically significant differences in liver function tests among those treated with Tac versus CsA in the short-term follow-up.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/basiliximab,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0041-1345
|
pubmed:author |
pubmed-author:ForoncewiczBB,
pubmed-author:GornickiJJ,
pubmed-author:KrawczykMM,
pubmed-author:MuchaKK,
pubmed-author:NiewczasMM,
pubmed-author:NyckowskiPP,
pubmed-author:Oldakowska-JedynakUU,
pubmed-author:PaczekLL,
pubmed-author:PatkowskiWW,
pubmed-author:SenatorskiGG,
pubmed-author:WyzgalJJ,
pubmed-author:ZegarskaJJ,
pubmed-author:Ziarkiewicz-WroblewskaBB,
pubmed-author:ZieniewiczKK,
pubmed-author:ZiolkowskaBB
|
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2281-3
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14529915-Acute Disease,
pubmed-meshheading:14529915-Antibodies, Monoclonal,
pubmed-meshheading:14529915-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:14529915-Cyclosporine,
pubmed-meshheading:14529915-Drug Therapy, Combination,
pubmed-meshheading:14529915-Graft Rejection,
pubmed-meshheading:14529915-Humans,
pubmed-meshheading:14529915-Immunoglobulin G,
pubmed-meshheading:14529915-Immunosuppressive Agents,
pubmed-meshheading:14529915-Incidence,
pubmed-meshheading:14529915-Liver Function Tests,
pubmed-meshheading:14529915-Liver Transplantation,
pubmed-meshheading:14529915-Mycophenolic Acid,
pubmed-meshheading:14529915-Recombinant Fusion Proteins,
pubmed-meshheading:14529915-Retrospective Studies,
pubmed-meshheading:14529915-Tacrolimus
|
pubmed:year |
2003
|
pubmed:articleTitle |
Effect of immunosuppressive regimen on acute rejection and liver graft function.
|
pubmed:affiliation |
Department of Immunology, Transplant Medicine, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
|
pubmed:publicationType |
Journal Article
|